Aaron C. Tan

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer

Stephen V. Liu, Caroline E. McCoach, Viola W. Zhu et al. · Annals of Oncology · 2020 · 216 citations · Full text

FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma

Aaron C. Tan, Louise Emmett, Serigne Lo et al. · Annals of Oncology · 2018 · 150 citations · Full text

Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis

Aaron C. Tan, Gillianne Lai, Gek San Tan et al. · Lung Cancer · 2019 · 117 citations

Cost-effectiveness Analysis, Medicine, Next-generation Sequencing +8

Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial

Shelagh B. Coutts, Sandeep Ankolekar, Ramana Appireddy et al. · The Lancet · 2024 · 101 citations · Full text

Thrombosis, Superiority Trial, Ischemic Stroke +12

Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC

Joe Yeong, Lisda Suteja, Yannick Simoni et al. · Journal of Thoracic Oncology · 2021 · 86 citations

Cancer Immunosurveillance, Medicine, Apoptosis +7